Result of GM

RNS Number : 8655J

Genedrive PLC

07 December 2018

 

7 December 2018

genedrive plc ("genedrive" or the "Company")

Result of General Meeting

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 19 November 2018 which is available on the Company's website http://www.genedriveplc.com/.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 15,217,391 Placing Shares.  It is expected that Admission will become effective at 8.00 a.m. on 10 December 2018.  Following Admission, the Company will have 34,000,506 Ordinary Shares in issue. No shares have been issued under the Broker Option.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.

-  Ends -

For further details please contact:

genedrive plc David Budd: CEO Matthew Fowler: CFO		[phone]
Peel Hunt LLP James Steel Oliver Jackson		[phone]
Stanford Capital Partners Limited Patrick Claridge		[phone]
John Howes
Consilium Strategic Communications Chris Gardner Matthew Neal Laura Thornton		[phone] [e-mail]

Notes to Editors

About genedrive

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

 

END

 

 

ROMBSBDDRUGBGIR